General
Lupin Neurosciences is committed to working with Healthcare Professionals to develop science-based solutions that stretch beyond access to lifechanging treatment options to optimize patient care in underserved neurological diseases.
Late breaker: Post-authorization safety study (PASS). Mexiletine effectiveness in patients with non-dystrophic myotonia: interim analysis finding
WMS abstract: WMD congress abstract PASS
WMS poster: PASS WMS 2024 FINAL